Mavyret Glecaprevir/Pibrentasvir 100mg/40mg Tablets

Mavyret is a fixed-dose combination medication containing glecaprevir and pibrentasvir, designed for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older. This medication is effective against multiple HCV genotypes (1, 2, 3, 4, 5, or 6) and is suitable for patients with or without compensated cirrhosis.

• Combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
• Indicated for patients previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor.
• Suitable for pediatric patients 3 years and older.

• Active Ingredients Glecaprevir 100mg, Pibrentasvir 40mg
• Dosage Form Tablet
• Administration Oral, with food

Primarily used for treating chronic hepatitis C in various genotypes.

Healthcare providers, patients with chronic HCV infection.

AbbVie Inc, the manufacturer of Mavyret, is a leader in the pharmaceutical industry, known for its innovative treatments for chronic diseases, including hepatitis C.